Physician profile
Michael A Notte
NPI 1821080219
$1,269.39
in general payments reported to CMS, 2019-2025
15 companies · $25.93 in 2025
The $25.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $165 · 2022: $189 · 2024: $75.32 · 2025: $25.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $267.93 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $192.38 | 2019-2022 | |
| Lilly USA, LLC | $160.68 | 2019-2024 | Mounjaro |
| Edwards Lifesciences Corporation | $155.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $131.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $95.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $59.00 | 2019 | |
| Pfizer INC. | $29.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.55 | 2019 | |
| Abbvie INC. | $22.59 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.33 | 2024 | Voquezna |
| Amarin Pharma, INC. | $14.62 | 2019 | |
| Appliedvr INC | $13.86 | 2024 | Relievrx |
| Merck Sharp & Dohme LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Notte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.